We designed a four-arm randomized controlled trial to investigate the median effective concentration (EC50) of propofol in combination with different doses of esketamine inducing appropriate depth of anaesthesia during gastrointestinal endoscopy in adults. One hundred patients aged 18–65 years planning for gastrointestinal endoscopy were divided into four groups randomly: esketamine 0, 0.15, 0.25 and 0.5 mg/kg groups (n = 25). Propofol doses followed the Dixon and Massey up-and-down method with different starting between groups. The primary endpoint was the EC50 of propofol. Secondary outcomes included the cumulative dose of propofol, the duration of the procedure, recovery time, and adverse effects. The EC50 (median, 95% confidence interval) of propofol was significantly less in the esketamine 0.5 mg/kg group compared with the esketamine 0, 0.15, and 0.25 mg/kg groups [1.34 (1.15, 1.54) vs. 3.48 (3.25, 3.71), 2.82 (2.58, 3.07), and 2.36 (2.11, 2.61), respectively; p < 0.001]. The total dose of propofol (mean ± SD) required for the whole procedure was significantly less in the esketamine 0.5 mg/kg group compared with the esketamine 0, 0.15, and 0.25 mg/kg groups [95.5 ± 43.1 vs. 277.4 ± 49.0, 207.8 ± 31.6, and 135.1 ± 27.7, respectively; p < 0.001]. The recovery time was significantly longer in esketamine 0 and 0.5 mg/kg group compared with other two groups (p < 0.001). More patients in the esketamine 0.5 mg/kg group experienced visual disturbance compared with the other groups (p = 0.016). Additionally, the incidence of hypotension in the esketamine 0 mg/kg group after induction was higher compared with other groups (p < 0.001). In summary, the administration of esketamine significantly and dose-dependently reduced the dose of propofol required to accomplish procedures.

**KEYWORDS**
esketamine, propofol, gastroscopy, colonoscopy, median effective concentration
Introduction

Gastroscopy and colonoscopy are important and common endoscopic methods for the diagnosis and treatment of gastrointestinal and colorectal diseases, such as the screening of early gastric cancer. They are invasive procedures and may cause stress reactions in the body, such as nausea, retching, vomiting, abdominal pain, abdominal distension, tachycardia and hypertension (Zheng et al., 2018). Painless endoscopy can effectively relieve the pain and discomfort of patients, and has become the preferred clinical diagnosis and treatment measure. Because the process is typically brief, the need for anaesthetic might have a quick onset and wake-up time, improving the work effect.

Despite widespread use and expertise, there is no standardized drug protocol for this condition (Li et al., 2019). How to improve the effect of sedation and analgesia, to choose a safe and reliable anaesthesia regimen has been the focus and difficulty of clinic. Propofol is widely used in procedural sedation/anaesthesia due to its rapid onset, rapid metabolism and minimal side effects (Shinsuke et al., 2014). However, propofol may result in hypotension, bradycardia, and respiratory depression. Researches (Zhou et al., 2016; Li et al., 2019; Thompson et al., 2019) have shown that the use of propofol combined with an adjuvant, such as ketamine or an opioid (sufentanil), for procedural sedation/anaesthesia is more efficacious and safe compared with either an opioid/benzodiazepine combination or propofol alone. Ketamine has irreplaceable advantages in maintaining spontaneous breathing and sympathomimetic properties, the combination of ketamine and propofol is preferred over the combination of opioids and propofol, for the latter may increase the possibility of respiratory depression.

Esketamine is an N-methyl-D-aspartate receptor antagonist, has similar pharmacological effects to ketamine, such as anaesthetic, analgesic and sympathomimetic properties (SmithApeldoorn et al., 2020; Bonaventura et al., 2021). Studies (Wang et al., 2019; Eberl et al., 2020) have shown the advantages using esketamine combined with propofol. However, no study has reported the optimal esketamine-propofol proportion during endoscopic procedures.

Therefore, we conducted a double-blind randomised controlled trial to determine the median effective concentration (EC50) of propofol combination with different doses of esketamine and explore the type and frequency of adverse events associated with the propofol-eketamine dose combinations.

Materials and methods

Study design and patients

This single-centre, prospective, randomised, controlled, double-blinded trial was performed from January 2022 to August 2022 at Shanxi Bethune Hospital, Shanxi, China. The protocol was approved by the local ethics committee (Medical Ethics Committee of Shanxi Bethune Hospital) and registered at Chinese Clinical Trial Registry (http://www.chictr.org, ChiCTR2100044567). After informed written consent of patient, we included 100 subjects aged 18–65 years, American Society of Anesthesiologists (ASA) class I or II, BMI 18.5–27, 9 kg/m2, undergoing painless gastrointestinal endoscopy. Exclusion criteria included: 1) allergy to any of the drugs used in the study; 2) preoperative use of analgesic and sedative drugs, or have a history of heavy smoking, alcohol abuse, serious drug abuse, and severe systemic infections; 3) renal or hepatic dysfunction; 4) a history of unregulated or malignant hypertension, significant heart disease, elevated intracranial pressure and intraocular pressure, psychiatric disease, pregnancy or suckling period.

Randomisation and masking

Subjects were allocated sequentially using random number generating computer software in a 1:1:1:1 ratio to receive one of four doses of esketamine: 0 (control group), 0.15, 0.25, or 0.5 mg/kg. Randomisation envelopes containing the study medication data were prepared. The envelopes were opened by the single study investigator (C.P.) preparing the study medication immediately before the patient arrived in the operating theatre. The investigator collecting data, patients and their guardians, endoscopists and nurses were blinded to the study medication. The allocation sequence was not available to any member of the research team until databases had been completed and locked.

Procedures

All patients were fasted at least 8 h before the gastrointestinal endoscopy. After intravenous access was obtained, an infusion of 250 ml NaCl 0.9% was started. Pulse oximetry, electrocardiography and blood pressure were routinely monitored, and patients were asked to position the mselveins lateral decubitus position, and oxygen was given for 4 L/min through a nasal catheter. The study investigator (C.P.), who did not participate in anesthesia during the endoscopy, prepared the study medications. The dose of esketamine was drawn into a 10 ml syringe and saline was added to produce a 10 ml solution. Patients were sedated using a TCI of propofol (Diprivan1%; Corden Pharma S.P.A, Caponago, Italy). We used the Gracey 3500 (AstraZeneca, United Kingdom) infusion pump preprogrammed for propofol TCI in the Marsh model.

Lidocaine 1%, 0.05 mg/kg was administered i.v. to minimise pain from propofol injection (Parmar and Koay, 1998). Approximately 10 s after lidocaine administration, propofol was injected. After the patient’s eyelash reflexes disappear, esketamine was administered according to the
study group assignment. Propofol TCI was initiated before administration of esketamine to avoid possible psychogenic effects of esketamine (Eberl et al., 2020). Two minutes after the administration, endoscope insertion was attempted and the patient’s response was recorded. If the patient was apneic, endoscope insertion was delayed until spontaneous ventilation resumed. If the patient was still too responsive to tolerate the procedure, additional doses of propofol 0.5–1 mg/kg was provided. After examination patients were transferred to the recovery room, and they had to stay in the recovery room for at least 30 min. Patients were discharged home once awake and with vital signs in the normal range, able to ambulate without assistance, and without significant side effects such as nausea.

**Determination of EC50**

We used an "up-and-down" titration method as described to determine of EC50 of propofol (Dixon, 1991; Pace and Stylianou, 2007). For each group, the starting propofol dose of the first patient was estimated to be close to the anticipated EC50 (Table 1) (Hayes et al., 2018). A positive response was defined as coughing, gagging, or excessive movement, that prevented complete insertion of the endoscope. If the response of the preceding patient was positive, the starting propofol dose in the subsequent patient in each group was increased by 0.5 μg/ml. The starting propofol dose in the subsequent patient in each group was decreased by 0.5 μg/ml if the previous patient tolerated complete insertion of the endoscope.

**Secondary end-point parameters**

The heart rate (HR), and pulse oxygen saturation (SpO2) were monitored constantly until discharge, and the non-invasive arterial blood pressure (SBP/DBP/MAP) was measured at three minutesintervals throughout the procedure. All vital signs were recorded at the following six time points: before induction of anesthesia (T0; baseline), at the end of anaesthesia induction (T1), at the time of endoscope insertion (T2), at the end of endoscopy (T3), when patients arrived at PACU (T4) and when patients awoke (T5). Patients with severe hypotension (systolic blood pressure [SBP] of <80 mmHg) or bradycardia (HR of <45 bpm) during the procedure who required rescue cardiovascular drugs were excluded from the study, the same effect-site concentration was used for the substitute patient.

The cumulative dose of propofol during the procedure, and the duration of the procedure (time of scope insertion to time of scope removal). Recovery time is defined as the time when propofol is stopped until the patient is awake without associated complications.

During the procedure, the following adverse events were recorded: the occurrence of hypotension, the occurrence of respiratory depression (SpO2 < 90%, lasting for at least 10 s), need for airway management: such as jaw thrust, insertion of oropharyngeal or nasopharyngeal airway, or positive pressure ventilation. During the recovery room, the following adverse events were recorded: the occurrence of nausea/vomiting, dizziness, visual disturbance, such as blurred or double-vision, nystagmus, and hallucinations.

**Statistical analysis**

The primary end point was to determine the EC50 of propofol with esketamine at 0, 0.15, 0.25 and 0.5 mg/kg for gastrointestinal endoscopy in adults. The second outcomes were total dose of propofol, recovery time, perioperative adverse events and so on. The EC50 of propofol calculated as the average of midpoints of failure-success crossovers, a probit analysis was used to estimate the EC95 value.

Numerical data were analyzed using a one-way ANOVA, Bonferroni method was used for comparison tests between groups, and categorical data were analyzed with the χ² test. The alterations of the MAP and HR were evaluated by a repeated measure analysis of variance (ANOVA). Continuous data are reported as mean (SD), or median and interquartile range, as appropriate. Categorical data are reported as frequencies (%). A value of p < 0.05 were considered statistically significant. The analysis was performed using SPSS for Windows (version 22.0; SPSS, Inc., Chicago, IL, United States).

The sample size was calculated according to the stop rule of the up-and-down sequential methodology, in each group, at least six cross overs are needed for accurate EC50 calculation, and anesthesia.

**TABLE 1 Drug dosage of esketamine and propofol for each group.**

| Group | Esketamine dose (mg/kg) | Propofol starting dose (μg/ml) | Dose interval (μg/ml) |
|-------|------------------------|-------------------------------|---------------------|
| E₀    | 0                      | 3                             | 0.5                 |
| E₁    | 0.15                   | 2.5                           | 0.5                 |
| E₂    | 0.25                   | 2                             | 0.5                 |
| E₃    | 0.5                    | 1.5                           | 0.5                 |
trials using Dixon’s up and down method typically have 20–40 patients (Pace and Stylianou, 2007; Feng et al., 2020; Oron et al., 2022; Zheng et al., 2022).

**Results**

109 patients were approached; eight declined to participate and one participant was excluded because of not meeting inclusion criteria (Figure 1). There were no significant differences in demographic data or procedural factors among subjects in the four groups (Table 2). The Dixon up-and-down sequences for each group are presented in Figure 2. The EC_{50} (95% CI) of propofol was significantly lower in the esketamine 0.5 mg/kg group compared with the esketamine 0, 0.15, and 0.25 mg/kg groups [1.34 (1.15, 1.54) vs. 3.48 (3.25, 3.71), 2.82 (2.58, 3.07), and 2.36 (2.11, 2.61), respectively; p < 0.001]

---

### TABLE 2 Patient characteristics.

| Esketamine group (dose mg/kg) | 0 (n = 25) | 0.15 (n = 25) | 0.25 (n = 25) | 0.5 (n = 25) | p value | F/Chi-square value |
|-----------------------------|------------|---------------|---------------|-------------|---------|-------------------|
| Gender (M/F)                | 14/11      | 12/13         | 15/10         | 11/14       | 0.659   | 1.603             |
| Age (yr)                    | 52.6 ± 6.5 | 54.4 ± 8.7    | 53.9 ± 6.9    | 50.7 ± 9.3  | 0.357   | 1.091             |
| Height (cm)                 | 166.2 ± 7.4| 164.8 ± 7.2   | 164.2 ± 5.9   | 163.8 ± 7.8 | 0.641   | 0.562             |
| Weight (kg)                 | 62.8 ± 7.9 | 62.0 ± 6.8    | 61.6 ± 6.8    | 62.9 ± 9.8  | 0.927   | 0.155             |
| BMI (kg/m2)                 | 22.7 ± 2.2 | 22.8 ± 2.0    | 22.8 ± 1.7    | 23.3 ± 2.3  | 0.712   | 0.458             |
| ASA (I/II)                  | 17/8       | 16/9          | 17/8          | 19/6        | 0.828   | 0.888             |
| Duration of procedure (min) | 16.3 ± 2.3 | 16.4 ± 2.5    | 16.1 ± 2.6    | 16.9 ± 4.0  | 0.808   | 0.325             |
| Total dosage of propofol (mg)| 277.4 ± 49.0| 207.8 ± 31.6  | 135.1 ± 27.7 | 95.5 ± 43.1| <0.001* | 107.411           |
| Awakening time (min)        | 10.9 ± 2.6 | 7.4 ± 2.6     | 7.4 ± 2.6     | 12.7 ± 3.1  | <0.001* | 22.377            |

Note: Data are presented as mean ± SD or number, as appropriate. *A value of p < 0.001 was considered significant.
There was no statistically significant difference between the ketamine 0.15 and 0.25 mg/kg groups. The total dose of propofol (mean ± SD) required for the whole procedure was significantly less in the esketamine 0.5 mg/kg group compared with the esketamine 0, 0.15, and 0.25 mg/kg groups (95.5 ± 43.1 vs. 277.4 ± 49.0, 207.8 ± 31.6, and 135.1 ± 27.7, respectively; \( p < 0.001 \)). The recovery time was significantly longer in the esketamine 0 and 0.5 mg/kg groups compared with other two groups (\( p < 0.001 \); Table 2).

As shown in Figure 3, in the esketamine 0.5 mg/kg group, the HR of T1 and T2 increased significantly (\( p < 0.05 \)) compared with T0. At the end of anesthesia induction (T1), the HR in esketamine 0.5 mg/kg group was significantly higher than that in esketamine 0, 0.15, and 0.25 mg/kg groups (\( p < 0.05 \)). There was a significant decrease in MBP in esketamine 0 and 0.15 mg/kg groups after finishing induction (T1), MBP of T1, T2 and T3 were significantly lower than that of baseline in the esketamine 0 mg/kg group (\( p < 0.05 \)). While in the esketamine 0.5 mg/kg group, there was a significant increase in MBP after finishing induction (T1), and the MBP of T1 significant higher than those of T0, T2, and T3 of the same group (\( p < 0.05 \)). The MAP was significantly lower in the esketamine 0 mg/kg group compared with the other three groups after finishing induction (\( p < 0.05 \)). In contrast, The MAP was significantly higher in the esketamine 0.5 mg/kg group than in the other three groups (\( p < 0.05 \)).

### Table 3

| E0 (esketamine 0 mg/kg) | E1 (esketamine 0.15 mg/kg) | E2 (esketamine 0.25 mg/kg) | E3 (esketamine 0.5 mg/kg) | \( p \) value |
|-------------------------|---------------------------|---------------------------|---------------------------|----------------|
| Dixon–Massey EC50 (µg/mL) | 3.48 (3.25, 3.71) | 2.82 (2.58, 3.07) | 2.36 (2.11, 2.61) | 1.34 (1.15, 1.54) | <0.001* |
| Probit regression EC50 (µg/mL) | 3.53 (3.04, 4.04) | 2.97 (2.51, 3.50) | 2.41 (1.92, 2.92) | 1.29 (0.79, 1.77) | <0.001* |
| Probit regression EC95 (µg/mL) | 4.90 (4.32, 6.23) | 4.34 (3.75, 5.73) | 3.78 (3.20, 5.11) | 2.66 (2.10, 3.94) | <0.001* |

(Table 3). There was no statistically significant difference between the ketamine 0.15 and 0.25 mg/kg groups. The total dose of propofol (mean ± SD) required for the whole procedure was significantly less in the esketamine 0.5 mg/kg group compared with the esketamine 0, 0.15, and 0.25 mg/kg groups [95.5 ± 43.1 vs. 277.4 ± 49.0, 207.8 ± 31.6, and 135.1 ± 27.7, respectively; \( p < 0.001 \)]. The recovery time was significantly longer in the esketamine 0 and 0.5 mg/kg groups compared with other two groups (\( p < 0.001 \); Table 2).

As shown in Figure 3, in the esketamine 0.5 mg/kg group, the HR of T1 and T2 increased significantly (\( p < 0.05 \)) compared with T0. At the end of anesthesia induction (T1), the HR in esketamine 0.5 mg/kg group was significantly higher than that in esketamine 0, 0.15, and 0.25 mg/kg groups (\( p < 0.05 \)). There was a significant decrease in MBP in esketamine 0 and 0.15 mg/kg groups after finishing induction (T1), MBP of T1, T2 and T3 were significantly lower than that of baseline in the esketamine 0 mg/kg group (\( p < 0.05 \)). While in the esketamine 0.5 mg/kg group, there was a significant increase in MBP after finishing induction (T1), and the MBP of T1 significant higher than those of T0, T2, and T3 of the same group (\( p < 0.05 \)). The MAP was significantly lower in the esketamine 0 mg/kg group compared with the other three groups after finishing induction (\( p < 0.05 \)). In contrast, The MAP was significantly higher in the esketamine 0.5 mg/kg group than in the other three groups (\( p < 0.05 \)).
During the procedure, there was no significant difference in the occurrence of respiratory depression, nausea/vomiting, and dizziness among groups. More patients in the esketamine 0.5 mg/kg group experienced visual disturbance compared with the other groups. In addition, the incidence of hypotension in the esketamine 0 mg/kg group after induction was higher compared with other groups (Table 4). All the adverse events were self-limited and transient.

**Discussion**

We have demonstrated that the EC$_{50}$ of propofol to achieve satisfactory sedation conditions decreased as the dose of esketamine increased from 0 to 0.5 mg/kg in ASA I or II patients. Patients who received esketamine 0 mg/kg or 1 mg/kg had a high incidence of either propofol or esketamine-related adverse events.

To our knowledge, this is the first randomised controlled dose-finding study on the influence of esketamine on the EC$_{50}$ of propofol anaesthesia during gastrointestinal endoscopy in adults. Propofol is often used in combination with ketamine and opioids to improve efficacy and patient tolerance. Several studies (Wang et al., 2019; Eberl et al., 2020; Huang et al., 2022; Xu et al., 2022) have compared a single-dose combination of esketamine and propofol with propofol and other types of drugs in terms of side effects and degree of sedation undergoing minor procedures, with esketamine doses ranging from 0.15 to 0.5 mg/kg. Esketamine

---

**TABLE 4 Adverse events.**

|                      | Esketamine 0 mg/kg group | Esketamine 0.15 mg/kg group | Esketamine 0.25 mg/kg group | Esketamine 0.5 mg/kg group | p value | Chi-square value |
|----------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|---------|------------------|
| Hypotension          | 13                       | 1                           | 1                           | 0                           | <0.001* | 36.0             |
| Respiratory depression| 5                        | 3                           | 4                           | 1                           | 0.377   | 3.095            |
| Nausea/vomiting      | 2                        | 0                           | 0                           | 1                           | 0.286   | 3.780            |
| Dizziness            | 1                        | 2                           | 2                           | 3                           | 0.780   | 1.087            |
| Visual disturbance   | 0                        | 4                           | 3                           | 8                           | 0.016*  | 10.275           |

Note: Hypotension was defined as more than 20% decrease in MBP when compared to baseline. Respiratory depression was defined as oxygen saturation less than 90% and lasting for at least 10 seconds. Visual disturbances included blurred or double-vision, nystagmus, and hallucinations. *p < 0.05 was considered significant.
(0.5 mg/kg) has been proven to be safe and well tolerated in Chinese patients undergoing painless gastroscopy, with no serious adverse events (Wang et al., 2019). While a recent study (Zhan et al., 2022) showed that 0.2 mg/kg esketamine combined with propofol is safe and effective for painless gastrointestinal endoscopy. Eberl et al. (2020) demonstrated that low-dose esketamine (0.15 mg/kg) reduces the requirement of propofol for sedation during ERCP when compared with alfentanil. Since the optimal dose ratio of propofol to esketamine is unknown, the empirical medications carry a potential risk of overdose. Therefore, our study was designed specifically to assess the optimal esketamine-propofol proportion for the procedures.

Our findings show that EC50 of propofol when co-administration with 0.15, 0.25 or 0.5 mg/kg esketamine was decreased by 19.0%, 32.2% and 61.5% compared with 0 mg/kg group. Consistent with our results, a significant dose-dependent reduction in the EC50 of propofol by esketamine has been reported in elderly patients (Yang et al., 2021). In this study, patients were divided into three groups receiving 0, 0.25, and 0.5 mg/kg of esketamine, respectively. The results showed that EC50 of propofol when co-administration with 0.25 or 0.5 mg/kg esketamine was decreased by 33.6% and 53.7% compared with 0 mg/kg group.

It is well known that propofol may cause dose-dependent bradycardia and hypotension, due to reduced systemic vascular resistance and myocardial contractility (Claeys et al., 1988; Lee, 2004). Our study also showed that the incidence of hypotension was significantly higher in esketamine 0 mg/kg group than in the other groups. While propofol co-administration with 0.5 mg/kg esketamine, there was a significant increase in MBP after finishing induction, which may be due to the decrease of propofol dosage and the increase of cardiac output by esketamine (Kamp et al., 2021). Similarly, Xin et al. (2020) and Tu et al. (2021) also showed that propofol combined with esketamine had better hemodynamic stability. In contrast to previous study (Yang et al., 2021), our study found that esketamine 0.15 and 0.25 mg/kg groups had shorter recovery times than esketamine 0 and 0.5 mg/kg group. The difference in the recovery time between the two studies is due to the different definition of the recovery time. Also, we found a significant increase in the incidence of visual disturbances in the esketamine 0.5 mg/kg group, a known adverse effect of esketamine (Guo et al., 2022), which may also explain the longer recovery time in this group.

There are some limitations to the study that should be mentioned. The first is the lack of esketamine dose more than 0.5 mg, such as 1 mg/kg, the choice of esketamine doses was based on the clinical experience of the investigators and previous studies. Although a higher esketamine dose can reduce propofol dose and associated side effects more significantly, it may also significantly increase the incidence of esketamine-related adverse effects. The cognitive function changes and psychomimetic side effects caused by esketamine have been widely concerned, which could be dose-related (Zheng et al., 2022). Second, in this study, EC95 was calculated using data extrapolation and bootstrapping, and it has a relatively large 95% confidence interval value that should be interpreted with caution. Further research can be conducted using, for example, biased coin design up-and-down sequential method (BCD-UDM). Finally, only patients with ASA physical status I-II were included in this study; therefore, the results are not applicable to clinically critical patients.

Conclusion

In conclusion, this report suggests that increasing the dose of esketamine can significantly reduce the dose of propofol required to accomplish procedures, with a corresponding reduction in propofol associated hemodynamic changes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and the research was approved by Shanxi Bethune Hospital Medical Ethics Committee. The patients/ participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

MF and WZ managed the literature searches, designed the study, and wrote the first draft of the manuscript. GS interpreted the statistical analyses. WC and NZ contributed to the data administration. QX edited the language to improve the clarity of the manuscript. WZ instructed in the study approach and supervised the statistical analyses and their interpretation. All authors have contributed to and approved the final manuscript.

Funding

This research were supported by 1) China Zhongguancun Precision Medicine Science and Technology Foundation [#Z-
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Bonaventura, J., Lam, S., Carlson, M., Boehm, M., Gomez, J., Solis, O., et al. (2021). Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol. Psychiatry 26 (11), 6704–6722. doi:10.1038/s41380-021-01093-2

Claeys, M. A., Gepts, E., and Camu, F. (1988). Haemodynamic changes during anaesthesia induced and maintained with propofol. Br. J. Anaesth. 60 (1), 3–9. doi:10.1093/bja/60.1.3

Dixon, W. J. (1994). Staircase bioassay: The up-and-down method. Neuropsychobiology. Rev. 15 (1), 47–50. doi:10.1007/978-3-7643-74000-9

Eberl, S., Koers, L., van Hooff, J., de Jong, E., Hermannides, J., Hollmann, M., et al. (2020). The effectiveness of a low-dose esetamibe versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: A randomised controlled multicentre trial. Eur. J. Anaesthesiol. 37 (5), 394–401. doi:10.1097/EJA.0000000000001134

Feng, M., Qiu, J., Qian, W., Wan, L., Zhang, C., and Yao, W. (2020). Effect-site concentration of remifentanil for inhibiting cardiovascular responses to double-lumen tube intubation with airwayvideoendoscopy: A comparison with macintosh laryngoscopy. J. Clin. Anesth. 60 (C), 97–98. doi:10.1016/j.claneu.2019.09.009

Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., et al. (2022). Neurological adverse events associated WithEsketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front. Pharmacol. 13, 849758. doi:10.3389/fphar.2022.849758

Hayes, J., Matava, C., Pehora, C., El-Beheiry, H., Jarvis, S., and Finkelstein, Y. (2018). Determination of the median effective dose of propofol in combination with midazolam. Br. J. Anaesth. 121 (15), 2208–2214. doi:10.1093/bja/aey122

Lee, Y. (2004). Effects of propofol target-controlled infusion on haemodynamic and respiratory changes with regard to safety. J. Int. Med. Res. 32 (1), 19–24. doi:10.1177/14732300040320013

Liu, X., Ma, C., Qi, S., and Zhang, L. (2019). Combination of propofol and dezocine to improve safety and efficacy of anesthesia for gastroscopy and colonoscopy in adults: A randomized, double-blind, controlled trial. World J. Clin. Cases 7 (20), 3237–3246. doi:10.29998/wjcc.v7.i20.3237

Oron, A. P., Souter, M., and Fournier, N. (2022). Understanding research methods: Up-and-down designs for dose-finding. Anesthesiology 137 (2), 137–150. doi:10.1097/ALN.0000000000004282

Pace, N. L. and Stylianou, M. P. (2007). Advances in and limitations of up-and-down methodology: A précis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology 107 (1), 144–152. doi:10.1097/01.anes.0000267514.42592.2a

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Parmar, A. K., and Koyu, C. K. (1998). Pain on injection of propofol. A comparison of cold propofol with propofol premixed with lignocaine. Anaesthesia 53 (1), 79–83. doi:10.1111/j.1365-2044.1998.00248.x

Shinmura, K., Hiroshi, N., and Hirotsuki, K. (2014). Propofol sedation during endoscopic treatment for early gastric cancer compared to midazolam. World J. Gastroenterol. 20 (34), 11985–11990. doi:10.3748/wjg.v20.i34.11985

SmithApoloosoon, S. Y., Veraart, J. K. E., Kamphuis, J., Breeksema, J. J., van den Brink, W., Aan, H., et al. (2020). Ketamine as an anesthetic, analgesic and anti-depressant. Tijdschr. Psychiatr. 62 (8), 629–439.

Thompson, B., Seck, V., Rioradan, S., and Wong, S. (2019). Comparison of the effects of midazolam/fentanyl, midazolam/propofol, and midazolam/fentanyl/propofol on cognitive function after gastrointestinal endoscopy. Surg. Laparosc. Endosc. Percutan. Tech. 29 (6), 441–446. doi:10.1097/SLE.0000000000001879

Tu, W., Yuan, H., Zhang, S., Lu, F., Yin, L., Chen, C., et al. (2021). Influence of anesthetic induction of propofol combined with esetamibe on perioperative stress and inflammatory responses and postoperative cognition of elderly surgical patients. Am J. Transl. Res. 13 (3), 1701–1709.

Wang, J., Huang, J., Yang, S., Cui, C., Ye, L., Wang, S., et al. (2019). Pharmacokinetics and safety of esetamibe in Chinese patients undergoing painless gastroscopy in comparison with ketamine: A randomized, open-label clinical study. Drug Des. devel. Ther. 13, 4135–4144. doi:10.2147/DDDT.S224553

Xin, N., Yan, W., and Jin, S. (2022). Efficacy of analgesic propofol/esetamibe and propofol/fentanyl for painless induced abortion: A randomized clinical trial. Biomed. Res. Int. 2022, 5095282. doi:10.1155/2022/5095282

Xu, Y., Zheng, Y., Tang, T., Chen, L., Zhang, Y., and Zhang, Z. (202202). The effectiveness of esetamibe and propofol versus dezocine and propofol sedation during gastrointestinal endoscopy: A randomized controlled study. J. Clin. Pharm. Ther. 47, 1402–1408. doi:10.1097/jcpt.13678

Yang, H., Zhao, Q., Chen, H., Liu, W., Ding, T., Yang, B., et al. (2021). The median effective concentration of propofol with different doses of esetamibe during gastrointestinal endoscopy in elderly patients: A randomized controlled trial. Br. J. Clin. Pharmacol. 88 (3), 1279–1287. doi:10.1111/bcp.15072

Zhan, Y., Liang, S., Yang, Z., Luo, Q., Li, S., Li, J., et al. (2022). Efficacy and safety of subanesthetic doses of esetamibe combined with propofol in painless gastrointestinal endoscopy: A prospective, double-blind, randomized controlled trial. BMJ Gastroenterol. 22 (1), 391. doi:10.1186/s12876-022-02467-8

Zheng, H., Zhang, X., Li, L., Wang, Y., Wei, Y., Chen, Y., et al. (2018). Multicentre prospective cohort study evaluating gastroscopy without sedation in China. Br. J. Anaesth. 121 (2), 508–511. doi:10.1097/BMA.0000000000001402

Zheng, H., Shen, Y., Yang, Z., He, P., Wang, Y., Tao, Y., et al. (2022). ED50 and ED95 of propofol combined with different doses of esetamibe for children undergoing upper gastrointestinal endoscopy: A prospective dose-finding study using up-and-down sequential allocation method. J. Clin. Pharm. Ther. 47 (7), 1002–1009. doi:10.1097/jcpt.13635